Partners in Crime: Genes within an Amplicon Collude to Globally Deregulate Chromatin in Lymphoma

Min, Dong-Joon; Licht, Jonathan D.

doi:10.1016/j.ccr.2010.11.032

Cited by 4 publications

(4 citation statements)

References 11 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…JAK2 and KDM4C act synergistically to promote heterochromatin formation and enhance the transcription of oncogenic important genes in primary mediastinal B cell and HL. 120,149 In B cells, hypoxia induces important Hodgkin and RS cell characteristics, including PCGF2 and DUSP1 expression as well as KDM4C overexpression. 150 survival and initiate differentiation into Hodgkin and RS celllike phenotypes.…”

Section: Lymphomamentioning

confidence: 99%

“…Activated JAK2 migrates to the nucleus and phosphorylate histone tyrosine 41, thereby preventing the binding of HP1α at that site, while KDM4C demethylates H3K9me3 and H3K36me3. JAK2 and KDM4C act synergistically to promote heterochromatin formation and enhance the transcription of oncogenic important genes in primary mediastinal B cell and HL …”

Section: Altered Expression and Functions Of Kdm4s In Cancermentioning

confidence: 99%

See 1 more Smart Citation

Advances in histone demethylase KDM4 as cancer therapeutic targets

et al. 2020

View full text Add to dashboard Cite

The KDM4 subfamily H3K9 histone demethylases are epigenetic regulators that control chromatin structure and gene expression by demethylating histone H3K9, H3K36, and H1.4K26. The KDM4 subfamily mainly consists of four proteins (KDM4A‐D), all harboring the Jumonji C domain (JmjC) but with differential substrate specificities. KDM4A‐C proteins also possess the double PHD and Tudor domains, whereas KDM4D lacks these domains. KDM4 proteins are overexpressed or deregulated in multiple cancers, cardiovascular diseases, and mental retardation and are thus potential therapeutic targets. Despite extensive efforts, however, there are very few KDM4‐selective inhibitors. Defining the exact physiological and oncogenic functions of KDM4 demethylase will provide the foundation for the discovery of novel potent inhibitors. In this review, we focus on recent studies highlighting the oncogenic functions of KDM4s and the interplay between KDM4‐mediated epigenetic and metabolic pathways in cancer. We also review currently available KDM4 inhibitors and discuss their potential as therapeutic agents for cancer treatment.

show abstract

Section: Lymphomamentioning

confidence: 99%

Section: Altered Expression and Functions Of Kdm4s In Cancermentioning

confidence: 99%

Advances in histone demethylase KDM4 as cancer therapeutic targets

et al. 2020

View full text Add to dashboard Cite

show abstract

“…JMJD2C/KDM4C is another histone demethylase that exhibits oxygenase activity at the bi-and trimethylated Lys-9 in histone H3 [83], and this protein is involved in the development and self-renew of undifferentiated and embryonic stem cells for regulation of adipogenesis through hypoxia [74,[84][85][86]. It is considered as an amplified oncogene in different cancers such as sarcomatoid and esophageal carcinoma [87,88], myeloid leukemia [88,89], lymphoma [90][91][92], breast carcinoma [93,94], desmoplastic medulloblastoma [95], and glioblastoma multiforme [96,97]. JMJD2C could be a potential target for the development of specific treatments against those forms of cancer [36].…”

Section: Jmjd2cmentioning

confidence: 99%

Histone Demethylases in Cancer

et al. 2015

View full text Add to dashboard Cite

Epigenetic regulation, which involves with covalent modifications of DNA and the protein that bundles DNA, namely histones, is an exciting and variable phenomenon that affects normal cellular genetic character and contributes to human diseases. One key histone modification is methylation, regulated by methyl transferases and demethylases. Recent studies have demonstrated that histone demethylases as new therapeutic targets in different diseases including cancers. In this manuscript, we summarize the current view of the histone demethylase families and their role as activators or repressors of various genes in cancer. It has been demonstrated that hypoxia is a driving force for the regulation of histone demethylases in different cancers. We have also discussed the latest development of the role of hypoxia in regulating histone demethylases and its effects on tumor progression.

show abstract

“…In addition to these functions, JMJD2C has been associated with the emergence of different pathologies such as alopecia areata and autistic spectrum disorders [ 126 , 150 ]. It is also considered to be an important amplified oncogene in different types of cancer such as sarcomatoid and esophageal carcinomas [ 70 , 82 ], myeloid leukemia [ 71 , 72 ], lymphoma [ 73 , 74 , 80 ], breast carcinoma [ 75 , 76 ], desmoplastic medulloblastoma [ 81 ], and glioblastoma multiforme [ 77 , 78 ]. Although the mechanisms by which this protein is involved in the development of these types of cancer have not been fully understood, the characteristics of this protein have suggested JMJD2C as a potential candidate for the development of specific treatments against these forms of cancer [ 25 , 110 , 151 ].…”

Section: Histone Demethylases and Cancermentioning

confidence: 99%

Epigenetic Control and Cancer: The Potential of Histone Demethylases as Therapeutic Targets

Lizcano

García

2012

Pharmaceuticals

View full text Add to dashboard Cite

The development of cancer involves an immense number of factors at the molecular level. These factors are associated principally with alterations in the epigenetic mechanisms that regulate gene expression profiles. Studying the effects of chromatin structure alterations, which are caused by the addition/removal of functional groups to specific histone residues, are of great interest as a promising way to identify markers for cancer diagnosis, classify the disease and determine its prognosis, and these markers could be potential targets for the treatment of this disease in its different forms. This manuscript presents the current point of view regarding members of the recently described family of proteins that exhibit histone demethylase activity; histone demethylases are genetic regulators that play a fundamental role in both the activation and repression of genes and whose expression has been observed to increase in many types of cancer. Some fundamental aspects of their association with the development of cancer and their relevance as potential targets for the development of new therapeutic strategies at the epigenetic level are discussed in the following manuscript.

show abstract

Partners in Crime: Genes within an Amplicon Collude to Globally Deregulate Chromatin in Lymphoma

Cited by 4 publications

References 11 publications

Advances in histone demethylase KDM4 as cancer therapeutic targets

Advances in histone demethylase KDM4 as cancer therapeutic targets

Histone Demethylases in Cancer

Epigenetic Control and Cancer: The Potential of Histone Demethylases as Therapeutic Targets

Contact Info

Product

Resources

About